CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.3860
3.74%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0180
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.336
Open 1.316
1-Year Change 133.54%
Day's Range 1.316 - 1.416
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 19, 2024 1.3860 0.0500 3.74% 1.3360 1.4260 1.2960
Jul 18, 2024 1.3360 -0.0600 -4.30% 1.3960 1.4460 1.3160
Jul 17, 2024 1.4360 0.0400 2.87% 1.3960 1.5060 1.3960
Jul 16, 2024 1.4660 0.1000 7.32% 1.3660 1.4860 1.3660
Jul 15, 2024 1.3860 -0.0600 -4.15% 1.4460 1.4460 1.3360
Jul 12, 2024 1.4060 0.0600 4.46% 1.3460 1.4460 1.3160
Jul 11, 2024 1.3460 0.0400 3.06% 1.3060 1.4060 1.3060
Jul 10, 2024 1.3160 0.1000 8.22% 1.2160 1.3160 1.2160
Jul 9, 2024 1.2260 0.0100 0.82% 1.2160 1.2560 1.1860
Jul 8, 2024 1.2360 0.0300 2.49% 1.2060 1.3260 1.2060
Jul 5, 2024 1.2660 -0.0100 -0.78% 1.2760 1.3160 1.1760
Jul 3, 2024 1.2860 0.1200 10.29% 1.1660 1.3160 1.1260
Jul 2, 2024 1.1560 0.0200 1.76% 1.1360 1.2160 1.0960
Jul 1, 2024 1.2160 0.0200 1.67% 1.1960 1.2560 1.1260
Jun 28, 2024 1.2160 0.0600 5.19% 1.1560 1.2860 1.1160
Jun 27, 2024 1.1360 0.1100 10.72% 1.0260 1.1760 1.0260
Jun 26, 2024 1.0760 0.0300 2.87% 1.0460 1.1060 1.0060
Jun 25, 2024 1.0660 -0.0400 -3.62% 1.1060 1.1460 1.0560
Jun 24, 2024 1.1560 0.0600 5.47% 1.0960 1.2260 1.0960
Jun 21, 2024 1.1560 0.0900 8.44% 1.0660 1.1560 1.0360

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Nektar Company profile

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Nektar Therapeutics revenues decreased 33% to $101.9M. Net loss increased 18% to $523.8M. Revenues reflect United States segment decrease of 84% to $10.1M. Higher net loss reflects Non-cash interest expense on liabilities increase of 56% to $47.3M (expense), Interest income and other income (expens decrease of 86% to $2.6M (income).

Equity composition

Common Stock $.0001 Par, 04/11, 300M auth., 114,073,353 issd.Insiders own 0.39% . IPO: 5/94,2.15M shares @ $7.50 by Lehman Brothers. PO 12/97, 1.725Mshares @ $24.875 by Lehman Brothers. *NOTE: 2/97, 1.8M shsissued in private placement @ $18/shs. 8/00, 2-for-1 stock split. Sr B Conv. Pfd. $0.0001 Par, 0 o/s.

Industry: Pharmaceuticals (NEC)

455 Mission Bay Boulevard South
SAN FRANCISCO
CALIFORNIA 94158
US

People also watch

Gold

2,401.36 Price
-1.830% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 21:00 (UTC)
Spread 1.20

ETH/USD

3,490.37 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,526.60 Price
-1.140% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.60 Price
+3.230% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01167

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading